ERBB2 and breast carcinoma: Stratified analysis based uniquely on HER2 receptor status showed that the NLR-breast cancer association was more pronounced among HER2-negative breast cancers (multivariable OR (95% CI) = 1.87 (1.16–3.02), P-trend < 0.001).